Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ACRS Aclaris Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ACRS
Price (delayed)
$1.18
Market cap
$127.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.59
Enterprise value
$97.41M
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The
Highlights
Aclaris Therapeutics's EPS has decreased by 46% YoY but it has increased by 7% QoQ
Aclaris Therapeutics's quick ratio has increased by 36% QoQ but it has decreased by 23% YoY
ACRS's gross profit has plunged by 80% YoY and by 19% from the previous quarter
The company's net income has shrunk by 69% YoY
Key stats
What are the main financial stats of ACRS
Market
Valuations
Earnings
Shares outstanding
108.28M
Market cap
$127.77M
Enterprise value
$97.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.88
Price to sales (P/S)
8.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.48
Revenue
$17.78M
Gross profit
$2.64M
Operating income
-$141.08M
Net income
-$130.21M
EBIT
-$130.21M
EBITDA
-$129.52M
Free cash flow
-$12.35M
Per share
Balance sheet
Liquidity
EPS
-$1.59
EPS diluted
-$1.59
Free cash flow per share
-$0.1
Book value per share
$1.33
Revenue per share
$0.15
TBVPS
$1.62
Total assets
$198.09M
Total liabilities
$54.03M
Debt
$0
Equity
$144.07M
Working capital
$87.28M
Debt to equity
0
Current ratio
5.06
Quick ratio
4.91
Net debt/EBITDA
0.23
Margins
Efficiency
Dividend
EBITDA margin
-728.5%
Gross margin
14.9%
Net margin
-732.4%
Operating margin
-793.6%
Return on assets
-68.4%
Return on equity
-92.4%
Return on invested capital
-94.9%
Return on capital employed
-73.7%
Return on sales
-732.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACRS stock price
How has the Aclaris Therapeutics stock price performed over time
Intraday
-3.28%
1 week
-5.6%
1 month
0%
1 year
0%
YTD
-52.42%
QTD
-22.88%
Financial performance
How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$17.78M
Gross profit
$2.64M
Operating income
-$141.08M
Net income
-$130.21M
Gross margin
14.9%
Net margin
-732.4%
ACRS's net margin has plunged by 195% YoY and by 3.8% from the previous quarter
Aclaris Therapeutics's operating margin has plunged by 125% YoY and by 7% from the previous quarter
ACRS's gross profit has plunged by 80% YoY and by 19% from the previous quarter
The company's net income has shrunk by 69% YoY
Price vs fundamentals
How does ACRS's price correlate with its fundamentals
Growth
What is Aclaris Therapeutics's growth rate over time
Valuation
What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
0.88
P/S
8.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.48
Aclaris Therapeutics's EPS has decreased by 46% YoY but it has increased by 7% QoQ
ACRS's P/B is 76% below its 5-year quarterly average of 3.6 and 2.2% below its last 4 quarters average of 0.9
ACRS's equity is down by 7% QoQ
ACRS's P/S is 86% below its 5-year quarterly average of 58.7 but 23% above its last 4 quarters average of 6.6
The company's revenue fell by 43% YoY and by 5% QoQ
Efficiency
How efficient is Aclaris Therapeutics business performance
Aclaris Therapeutics's return on sales has shrunk by 194% YoY and by 3.8% QoQ
The company's return on equity has shrunk by 90% YoY
The ROA has plunged by 83% YoY but it has increased by 4.5% from the previous quarter
Aclaris Therapeutics's return on invested capital has shrunk by 73% YoY but it has increased by 6% QoQ
Dividends
What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACRS.
Financial health
How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's total liabilities has soared by 69% YoY but it has decreased by 17% from the previous quarter
Aclaris Therapeutics's quick ratio has increased by 36% QoQ but it has decreased by 23% YoY
ACRS's debt is 100% less than its equity
ACRS's equity is down by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.